Overview |
bs-6511R |
RNF45 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Rat |
Human, Mouse, Dog, Cow, Chicken, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human AMFR/RNF45 |
85-180/643 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
267 |
Cytoplasm, Cell membrane |
AMF receptor; AMF receptor isoform 1; AMF receptor isoform 2; AMFR; AMFR2_HUMAN; Autocrine motility factor receptor; Autocrine motility factor receptor precursor, isoform 1; Autocrine motility factor receptor precursor, isoform 2; E3 ubiquitin-protein ligase AMFR; gp78; RING finger protein 45; RNF 45; RNF45. |
E3 ubiquitin-protein ligase which can target both itself and other proteins including CD3D and APOB for proteasomal degradation. Mediates polyubiquitination of CYP3A4. Specific receptor for the autocrine motility factor. Mediates tumor invasion and metastasis. Component of a complex required to couple deglycosylation and proteasome-mediated degradation of misfolded proteins in the endoplasmic reticulun that are retrotranslocated in the cytosol. Promotes ubiquitination of misfolded proteins such as mutant CFTR; proposed to mediate sequential ubiquitination by recognizing already ubiquitin-conjugated substrates and to cooperate with E3 ubiquitin-protein ligase RNF5. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |